Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation

• Status: Recruiting
• Trial end date: 2021-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the present study is to investigate the effect of ACE inhibitors and the sacubitril-valsartan complex in bone marrow transplant patients by assessing cardiovascular and endothelial parameters in order to search for a potent protective role.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Athens
• Treatments: Angiotensin-Converting Enzyme Inhibitors; LCZ 696; Sacubitril and valsartan sodium hydrate drug combination; Valsartan

Criteria

Inclusion Criteria:

• Adolescents male and female

• that have just been treated with bone marrow transplantation due to haematological malignancies.

Exclusion Criteria:

• Coronary Artery Disease

• Permanent Atrial Fibrilation

• Signs of Left Ventricular Hypertrophy on electrocardiography or echocardiography

• Left ventricle Ejection Fraction<50% or segmental wall motion abnormalities of left ventricle

• More than moderate valvular disease

• Primary Myocardiopathy

• Blood Pressure<90 mmHg

• GFR<30 ml/min/1,73m2

• Unwilling to recruit

• Uncontrolled Arterial hypertension